TEVA: Innovative product growth and biosimilars drive raised outlook and strong cash flow in Q2 2026
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the Emalex acquisition and biosimilars expansion support long-term growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the Emalex acquisition and biosimilars expansion support long-term growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.